Please note – you will leave a website owned by MacroGenics, Inc.
MacroGenics is not responsible for any content on the third party website.
MGD013 is intended to enable co-blockade of two immune checkpoint molecules co-expressed on T cells, PD-1 and LAG-3, with a single agent. MGD013 is a Dual-Affinity Re-Targeting, or DART®, molecule that recognizes both PD-1 and LAG-3 on T cells and has a prolonged serum half-life. We anticipate that MGD013 could be used for the treatment of a wide range of cancers, including both solid tumors and hematological malignancies. MGD013 is the first in a series of pre-clinical product candidates that recognize multiple immune regulator targets; we anticipate submitting the Investigational New Drug (IND) application for MGD013 in 2017.
At its 2015 R&D Day, MacroGenics highlighted pre-clinical data showing that the co-blockade of PD-1 and LAG-3 via a PD-1 x LAG-3 DART molecule significantly enhanced T-cell response in a checkpoint inhibition assay as compared to each of the benchmark antibodies either individually or in combination.
MacroGenics retains full worldwide rights to MGD013.